gefitinib has been researched along with Injuries, Spinal Cord in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Chen, B; Dai, J; Dong, Q; Fan, C; Fan, Y; Fang, Y; Han, J; Han, S; Li, X; Liu, S; Liu, W; Ma, D; Wu, X; Xiao, Z; Xu, B; Xue, W; Xue, X; Yang, Y; Zhang, H; Zhao, Y | 1 |
1 other study(ies) available for gefitinib and Injuries, Spinal Cord
Article | Year |
---|---|
Epidermal growth factor receptor-extracellular-regulated kinase blockade upregulates TRIM32 signaling cascade and promotes neurogenesis after spinal cord injury.
Topics: Animals; Cells, Cultured; Cetuximab; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Flavonoids; Gefitinib; GTP-Binding Proteins; Mice; Mice, Inbred C57BL; Neurogenesis; Neurons; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Signal Transduction; Spinal Cord Injuries; Up-Regulation | 2020 |